<DOC>
	<DOCNO>NCT03042910</DOCNO>
	<brief_summary>This study design evaluate effect talazoparib cardiac repolarization patient advance solid tumor available standard treatment option .</brief_summary>
	<brief_title>A Study Assess Effects Talazoparib Cardiac Repolarization Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>For talazoparib treatment , patient must enroll initiate continue talazoparib treatment separate open label extension study within 30 day last dose study drug .</detailed_description>
	<mesh_term>Talazoparib</mesh_term>
	<criteria>1 . At least 18 year age willing able provide inform consent . 2 . Histologically cytologically confirm advanced solid tumor available standard treatment option opinion investigator . 3 . Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 . 4 . Estimated life expectancy ≥ 3 month . 5 . Able swallow study drug , know intolerance study drug excipients , comply study requirement . 6 . Female patient childbearing potential must negative pregnancy test screening must agree use highly effective birth control method time first dose study drug 45 day last dose study drug . 7 . Male patient must use condom sex pregnant woman woman childbearing potential time first dose study drug 105 day last dose study drug . Contraception consider nonpregnant female partner childbearing potential . 8 . Male female patient must agree donate sperm egg , respectively , first dose study drug 105 day 45 day last dose study drug , respectively . 9 . Female patient may breastfeed screen must breastfeed study participation 45 day last dose study drug . 1 . Use antineoplastic therapy within 21 day day 1 . 2 . Use investigational agent within 21 day day 1 . 3 . Have recover ( recovery define National Cancer Institute Common Terminology Criteria Adverse Events [ CTCAE ] grade ≤ 1 ) acute toxicity previous therapy , except treatment relate alopecia laboratory abnormality otherwise meet eligibility requirement . 4 . Electrolyte abnormality respond correction , include hypokalemia hypocalcemia less low limit normal , hyperkalemia hypercalcemia great upper limit normal ( ULN ) . 5 . Major surgery within 14 day day 1 . 6 . Diagnosis myelodysplastic syndrome ( MDS ) hematologic malignancy . 7 . Clinically significant cardiovascular disease . 8 . Significant organ dysfunction . 9 . Gastrointestinal disorder affect absorption . 10 . Current anticipate use strong Pgp inhibitor , strong Pgp inducer , strong inhibitor BCRP . 11 . Any condition ( concurrent disease , infection , comorbidity ) interfere ability participate study , cause undue risk , complicate interpretation safety data , opinion investigator medical monitor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>